Takeaway

• A new review article published in  JAMA Oncology  covers emerging developments around the approximately 50% of breast tumours that express low levels of the human epidermal growth factor receptor 2 (HER2), now called Erb-b2 receptor tyrosine kinase 2 (ERBB2).
• A major milestone came in June 2022 with the Food and...